|
Pleiad Devices Selects OmniComm Systems as their eClinical Solutions Provider
Fort Lauderdale, FL, August 25, 2009 -- OmniComm Systems, Inc.
(OTC Bulletin Board: OMCM.OB ), a leader in integrated electronic data capture
(EDC) solutions for clinical trials, announced today that their EDC tool, TrialMasterTM,
has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research
Organization (CRO) with European operations in the U.K., to provide eClinical services
to its customers. Pleiad’s investment will provide it with the products and services
to manage two upcoming studies investigating the use of ophthalmic medical devices.
This partnership is expected to generate more than $1 million to OmniComm over the
next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008
under OmniComm’s CRO Preferred Program, and is now transitioning to a Technology
Transfer model in order to provide greater value to its customers engaged in these
important clinical trials.
"We are pleased to once again be collaborating with Pleiad, as the exposure generated
from working closely on a continual basis with such a specialized, internationally
renowned CRO will undoubtedly raise our profile within the international clinical
community," commented Stephen Johnson, OmniComm’s COO. "We expect that as we continue
to work with well respected, high profile organizations such as Pleiad, we will
continue to attract companies of an equally high caliber to our dramatically enhanced
service offering. We feel that we can offer organizations engaged in clinical research
a significant advantage over their peers with our highly specialized portfolio of
eClinical solutions designed to greatly simplify the clinical process."
"TrialMaster has been an essential option for us to provide to our customers. Much
is made about the importance of subject compliance in clinical research, but we
find that study coordinator 'compliance' is also very critical. The TrialMaster
EDC system is very intuitive, so the study coordinators with whom we work have little
problem in getting their work completed within the allocated time," stated Stephen
Brandao, Pleiad’s Vice President of Business Development. "We find that OmniComm
is an attentive partner, very much in tune with the needs of our business. Our team
anticipates collaborating with them on future opportunities."
About Pleiad
Pleiad Inc., is a clinical CRO (contract research organization) that specializes
in expertly assisting medical device, combination, women’s health, and ophthalmic
product manufacturers meet the clinical, quality, safety and regulatory requirements
of the product development process. Their work encompasses the progression from
the conceptual and developmental stages to post-marketing trials, offering regulatory
support, clinical trial management, and safety monitoring services.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large scale institutions
to safely and efficiently capitalize on their clinical research investments. OmniComm
Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters
in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and
Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to uncertain
regulatory guidance, variability in size, scope and duration of projects, and internal
issues at the sponsoring client, integration of acquisitions, competitive factors,
technological development, and market demand. As a result, actual results may differ
materially from any financial outlooks stated herein. Further information on potential
factors that could affect the Company's financial results can be found in the Company's
Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.
The Company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
